

## **Neurology Grand Rounds**

Sponsored by Baylor College of Medicine

Monday, January 9, 2012 Noon – 1:00 PM Neurosensory Center, Blue Bird Auditorium, NB-137

## Why Is It Difficult To Develop New Treatments For AD?

## Rachelle S. Doody, MD, Ph.D.

Professor
Department of Neurology
Baylor College of Medicine

**Objectives** – At the conclusion of the session, the participants should be able to:

- Identify several barriers to developing new AD treatments
- Understand the role of biomarkers in selecting populations of AD patients
- List the AD treatments currently in Phase 3 development

**Target Audience, Needs, Educational Methods, Activity Evaluation:** Physicians, residents, fellows, and other healthcare professionals need to be updated about new advances in the clinical and research areas for the diagnosis, treatment, and management of patients with neurological disorders. Educational methods will include lectures, case presentations, audio/video presentations, and questions & answer sessions. Participants will be asked to complete an activity evaluation.

## **Accreditation/Credit Designation**

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1  $Credit^{TM}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.